Dr. Ryan D. Egeland Ph.D. serves as Chief Medical Officer of the Company. Prior to joining us, he held several roles in marketing, medical affairs and business development at Covidien and Medtronic from April 2012 to November 2017, most recently as Senior Director of Business Development & Licensing for Medtronic Surgical Innovations from February 2015 to November 2017. Prior to these roles, Dr. Egeland trained as a plastic and reconstructive surgeon at Northwestern Memorial Hospital and received an MD with honors from Harvard Medical School. Dr. Egeland also holds a PhD in biochemistry and engineering from the University of Oxford, where he also completed a MBA as a Rhodes Scholar.
As the Chief Medical Officer of Cardiovascular Systems, the total compensation of Ryan Egeland at Cardiovascular Systems is $963,833. There are 6 executives at Cardiovascular Systems getting paid more, with Scott Ward having the highest compensation of $4,718,960.
Ryan Egeland is 45, he's been the Chief Medical Officer of Cardiovascular Systems since 2017. There are 21 older and 4 younger executives at Cardiovascular Systems. The oldest executive at Cardiovascular Systems Inc. is Augustine Lawlor, 64, who is the Independent Director.
Ryan's mailing address filed with the SEC is 1225 OLD HIGHWAY 8 NW, , ST. PAUL, MN, 55112.
Over the last 16 years, insiders at Cardiovascular Systems have traded over $72,999,461 worth of Cardiovascular Systems stock and bought 949,532 units worth $8,687,068 . The most active insiders traders include Capital Management Lp Camber, Augustine Lawlor a Capital Ltdmaverick Capital.... On average, Cardiovascular Systems executives and independent directors trade stock every 14 days with the average trade being worth of $338,920. The most recent stock trade was executed by Martha Goldberg Aronson on 15 August 2022, trading 2,411 units of CSII stock currently worth $48,220.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.
Cardiovascular Systems executives and other stock owners filed with the SEC include: